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INTRODUCTION 
My Ph.D. work was to generate human artificial chromosome(s). Significance of the 
successful development of mammalian artificial chromosomes (MACs) is twofold. MACs 
would provide a unique model system for studying the structure and function of higher 
eukaryotic chromosomes. Further more, MACs would represent a non-integrating, optimal 
vector system with large carrying capacity for different areas of biotechnology, such as 
cellular protein production, transgenic animal technology including protein production and 
xenotransplantation, and gene therapy. Successful construction of MAC vectors would have a 
substantial impact on the further development of gene therapy. Considering this potential of 
human artificial chromosomes, below there is a brief summary about the basics of gene 
therapy [I]. 
1. What is gene therapy and why gene therapy? 
Despite advances in clinical practice, many diseases still have no cure and require 
expensive treatments to prolong the lifespan of patients. The idea that therapeutic gene transfer 
may permanently cure some diseases has sparked great interest in the field of gene therapy. 
The basic concept of gene therapy can be described as the intracellular delivery of 
genetic material to generate a therapeutic effect by correcting an existing abnormality or 
providing cells with a new function. 
Initially, inherited genetic disorders were the main focus of gene therapy, but now a 
wide range of diseases, including cancer, vascular diseases, neurodegenerative disorders and 
other acquired diseases are being considered as targets. At present, the suitability of a disease 
considered to be treated by gene therapy relies on several prerequisites: 
• The disease must be life threatening, thus making its treatment ethically acceptable to the 
risk of side effects. 
• The effects of disease must be potentially reversible by the treatment. 
• The gene must be fully characterized. 
• Delivery to the affected site must be feasible. 
• Well-defined short-term diagnostic parameters are required to demonstrate the 
physiological effect and benefit of the inserted gene. (For example, in the case of cystic 
fibrosis the electrical conductance change over the nasal epithelium can be monitored.) 
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On the basis of the target cells distinction can be made between therapy on the germ 
cells and the somatic cells of an individual. 
1.1. Germline gene therapy 
Germline engineering, in practice, today means altering the fertilized eggs - the first cell 
of the will-be-embryo - so that the genetic changes will be copied into every cell of the future 
adult, including his or her reproductive cells. Such changes would be passed to the offspring. 
Germline gene therapy is currently considered to be ethically unacceptable, even though 
it has the potential to eradicate many disorders. Until such time as gene therapy for many 
illnesses is commonplace, with all the difficulties to routine use of gene therapy overcome and 
side-effects identified and dealt with, germline gene therapy will not be attempted. Ultimately, 
the question of germline gene therapy will have to be re-evaluated and we may see many of 
inherited diseases disappear from the gene pool. 
"It seems obvious that germline therapy will be much more successful than 
somatic. If we wait for the success of somatic therapy, we'll wait until the sun 
burns out. We might as well do what we finally can to take the threat of 
Alzheimer's away from a family or breast cancer away from a family. The biggest 
ethical problem we have is not using our knowledge, ...people not having the guts 
to go ahead and try and help someone. We are always going to have to take 
chances." (James D. Watson)[2] 
1.2. Somatic gene therapy 
The somatic gene therapy involves delivery of genes into diploid cells of an individual 
where the "implanted" genetic material is not passed onto its progeny. Somatic interventions 
do not reach beyond the patient being treated. 
1.2.1. Ex vivo delivery 
In this system, genetic material is inserted after explanation, cultivation and 
manipulation of cells in vitro, followed by a subsequent re-implantation. For this purpose 
either differentiated or stem cells can be used. 
The ex vivo route is attractive mainly due to the reduced immunological problems and 
the enhanced efficiency of vector delivery in vitro. 
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So far, the only successful gene therapy clinical trial was carried out by applying the ex 
vivo delivery approach [3]. 
1.2.2. In vivo delivery 
The in vivo delivery involves two major approaches as the in situ delivery, and the 
systemic administration of the exogenous genetic material. 
The in situ delivery means the administration of the genetic material directly to the 
desired tissue. This approach offers effective targeting, but the continuing problem is the low 
efficiency of the delivery of therapeutic genetic information. 
Administration of genetic material systemically is probably the least advanced strategy 
at present, but potentially the most useful and desirable. The main hurdles of systemic delivery 
approach are the insufficient targeting of the current vectors to the correct tissue sites, the 
strong immune response stimulated by most of the vectors used to date, and that the 
therapeutic lipid-DNA complexes are rapidly eliminated after systemic administration. 
2. Delivery systems, vectors 
All gene therapy applications depend on the fact that genetic material needs to be 
delivered across the cell membrane and preferably to the cell nucleus. 
2.1. Viral systems 
Viruses have throughout evolution developed highly effective methods of entering cells 
and delivering their genetic information into the cells. 
Many viral vector systems now exist for use in gene delivery studies. Common to all 
viral vectors is the fact that they are genetically modified viruses, containing "foreign" genes 
and deleted areas, which render them replication incompetent. The most widely used virus-
based delivery systems are summarized below. 
2.1.1. Retroviral vectors (RV) 
Most current retroviral vectors for gene therapy purposes are based on the retroviral 
oncogenic subgroup Moloney murine leukemia virus (MoMuLV)[4]. The nonpathogenic 
retroviruses, human spumaviruses are also being examined as potential gene delivery vehicles 
as they are able to infect quiescent cells. Currently retroviral vectors derived from the 
lentivirus group are being developed because they provide a promising tool to facilitate 
retroviral mediated gene therapy [5,6]. 
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The removal of practically all of the viral genes provides an approximately 9-10kb of 
space for transgene incorporation. In this way infectious replication-incompetent virus 
particles can be generated. 
Advantages offered by replication-defective retroviruses: 
• Efficient and stable integration of the transgene into the host genome, enabling the long-
term expression of the transgene [7]. 
• The targeting of retroviruses to specific cell populations by engineering heterologous 
protein domains into the envelope glycoproteins that modifies their tropism [8]. 
There are drawbacks limiting the application of retrovirus-based vector system: 
• Inability to produce high titers of purified virus particles. 
• The possible contamination of retroviral stocks with replication-competent retroviruses or 
recombination of the replication-defective viruses with wild-type (retro-) viruses. 
• Size limitations on the amount of DNA, which can be stably incorporated into the 
retroviral cassettes to allow packaging into the retroviral particles. This limits the 
application of larger genes or large regulatory elements. 
• The risk of insertional mutagenesis of essential genes or activation of cellular oncogenes 
upon random integration into the host genome. 
• The conventional MoMuLV-based vectors, targeting only mitotically active cells, have 
limited gene delivery into targets such as muscle, neurons, hepatocytes and hematopoietic 
stem cells [5,9]. 
• Sensitivity of murine retroviruses to inactivation by the human complement-mediated lysis 
pathway of the immune system [10]. 
• The vector promoter silencing (promoter "shut-off') in stably transduced cells in vivo [11]. 
At present, the retrovirus-based vectors are the most widely used delivery vehicles in 
clinical trials accounting for approximately 40% of studies. A landmark gene therapy trial for 
X-linked SCID was successfully completed in two infants [3], based on the use of 
complementary DNA containing a defective Moloney retrovirus-derived vector and ex vivo 
infection of CD34+ stem cells. After a 10-month follow-up period, gammac transgene-
expressing T and NK cells were detected in the two patients. The T, B and NK cells counts 
and function, including antigen-specific responses, were comparable to those of age-matched 
controls. This clinical trial can be regarded as the first success of the gene therapy because 
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gene therapy was able to provide full correction of disease phenotype and, hence, clinical 
benefit. 
2.1.2. Adenoviral vectors (Ad) 
The adenovirus-based vectors are also commonly used for gene therapy applications. 
Adenoviruses types 2 and 5 are thought to be suitable as vectors for gene therapy purposes and 
recombinant adenovirus vaccines, since they are not implicated in serious illness [12]. 
The first generation adenovirus vectors are deleted in the El region - resulting in 
approximately 7.8kb [13] space to incorporate exogenous DNA sequences -, theoretically 
rendering the adenovirus unable to replicate in non-El complementing cell lines [14,15]. 
Although deleted for El function, first generation adenovirus-based vectors were found to 
result in low level leaky expression of the remaining viral genes initiated by the host El-like 
transcription factors [16]. 
Second generation adenovirus vectors are being designed to be less immunogenic to the 
infected host, aiming at complete ablation of expression of the immunodominant viral proteins 
facilitating persistent long-term expression. As well as minimizing the leaky expression of 
highly immunogenic adenoviral proteins, these deletions increased the cloning capacity of the 
vectors. On the other hand, deletion of more than one essential regulatory element reduces the 
risk of the emergence of replication competent adenovirus from genetic recombination with 
adenovirus sequences in ¿raws-complementing cell line or from endemic wild-type adenovirus 
infections. 
More recently a new generation of the adenoviral system has been developed in which 
practically all of the viral genome has been deleted. These so-called "gutless" or "pseudo" 
adenoviruses (PAV) have a transgene capacity up to 37kb. 
The major advantages of the adenovirus-based vectors: 
• Their limited pathogenicity. 
• Wide host range and tropism for most of the human cells. 
• High infectivity in vitro and in vivo. 
• The ability to infect quiescent as well as dividing cells [17]. 
• The adenovirus genome rarely integrates into the host chromosome and therefore 
replicates in an extra-chromosomal state, minimizing the genotoxicity associated with 
insertional mutagenesis [18]. 
• The ability to produce high numbers of purified particles. 
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Disadvantages of the adenoviral system: 
• Current adenovirus vectors have a relatively tight restriction on the size of DNA, which 
can be packaged into virions [14]. 
• Since adenovirus-delivered genes are episomally maintained and lost due to genetic 
instability, they are expressed transiently. Hence repeated administrations are necessary to 
maintain stable expression of the transgene. 
• High immunogenic feature of the virus particles and their gene products, which limits the 
number of repeated applications in vivo. Host immune responses result in transient gene 
expression in vivo [16,19,20], ultimately leading to the loss of transgene expression due to 
eradication of successfully transduced cells [20]. 
The adenoviral vehicle system is particularly attractive to the cystic fibrosis therapists 
and also could be used in cancer gene therapy, where enhanced cell death due to immune 
recognition is desirable. 
The first victim of the gene therapy trials was the 18-year-old patient, Jesse Gelsinger, a 
participant in the experimental gene therapy trial for ornithine transcarbamilase (OTC) 
deficiency. He died four days after being injected with corrective genetic material using an 
adenoviral-based vector system. The cause of his death was that the modified "cold" 
adenovirus-based vector initiated an unusual and deadly immune-system response that led to 
multiple organ failure and death [21]. 
2.1.3. Adeno-associated viral vectors (AAV) 
The AAV is naturally replication incompetent and requires additional genes from a 
helper virus infection which in nature are generally complemented by adenovirus or herpes 
simplex virus coinfection [22]. The wild-type AAV has been demonstrated to preferentially 
integrate into human chromosome #19 at site ql3.4 directed by the rep gene [23,24]. (This 
chromosomal region is thought to be involved in malignant transformation events of cells.) 
AAV-based vectors generally involve replacement of the rep and cap genes with a 
transgene of interest [24]. 
The AAV-based vector system offered advantages: 
• High transduction frequencies. 
• The ability to infect all cultured cells tested [24], and in vivo (systematic) applications 
have resulted in the transduction of the majority of tissues. 
• The ability of preparation of high titers. 
E. Csonka: Generation of prototype human satellite DNA-based artificial chromosomes 
10 
The rep deleted AAV vectors has a number of limitations at present: 
• Complicated process of vector production. 
• The purified stocks easily contaminated with wild-type AAV and helper viruses [24]. 
• As the rep functions are deleted, the assembled virions lose the ability to selectively 
integrate into the host genome and tend to integrate randomly, introducing the same risk of 
insertional mutagenesis as retroviruses [23], 
• The limited transgene capacity of the particles, which is approximately 4.7kb [24]. 
2.1.4. Herpesvirus-based vectors 
The current herpesvirus vectors are based on the herpes simplex virus (HSV) type 1. The 
HSV based systems include the development of the so-called disabled infectious single copy 
(DISC) virus which comprises a glycoprotein H defective mutant HSV genome. Viral particles 
generated in complementing cells can infect any other cells, replicate their own genome but 
will not produce further infectious particles. 
Current HSV-based vectors involve replacement of one or more of the five immediate 
early (IE) genes whose functions are ¿rans-complemented by packaging cell lines [25,26]. The 
major interest comes from the possibility of a "gutless" HSV vector, which has the potential of 
accommodating up to 150kb of insert DNA [27]. 
Advantageous features: 
• HSV has a wide tropism, infecting virtually any human cell, and is capable of nuclear 
delivery, infecting dividing as well as quiescent cells [25]. 
• Herpesviruses infect and persist in cells of the nervous system, hence herpesvirus-based 
vectors may provide a unique strategy for gene transfer to cells of the nervous system [28]. 
Limitations: 
• As the HSV genome is episomally maintained in the nucleus of the infected host, they 
provide only transient gene expression. 
• The insert capacity of the current HSV based vectors is approximately 20kb. 
• Immunogenic features due to the viral proteins expressed in the infected host cells. 
• The risk of the emergence of replication competent herpes virus from genetic 
recombination with herpesvirus sequences in /raws-complementing cell line or from wild-
type herpesvirus infections. 
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2.1.5. Other viral vectors and hybrid vector systems 
Although the RV, Ad, AAV and HSV are currently the most advanced viral vector 
systems applied in gene therapy trials, a large number of other viruses have potential: 
poliovirus, vaccinia virus, cytomegalovirus, measles virus, pseudorabies virus, baculovirus 
(insect virus) and parvovirus [29] are being developed for gene therapy. Hybrid vectors are 
also being developed which combine advantageous properties of current viral vector systems 
into single systems, generating novel viruses with unique combinations of functions [30]. 
2.2. Nonviral systems 
Alternatives to the viral strategies are the application of chemically synthesized vehicles, 
delivery by physical methods or receptor mediated gene transfer. 
2.2.1. Chemical delivery systems 
The vast majority of current chemical delivery systems are based on polycationic entities 
which cause compaction of negatively charged nucleic acids accompanied by the formation of 
nanometric complexes: lipoplexes or polyplexes [31]. These polycationic entities belong to 
one of two main categories which are either cationic liposome/micelle (DOPE, DOTMA [32], 
DOTAP [33] etc.) or cationic polymer-based (poly-L-lysine [34], polyamidoamine [35], 
polyethylenimine [36,37] etc.). These nanometric complexes are generally stable enough to 
protect bound nucleic acids from degradation and are able to enter cells, usually by 
endocytosis. Inside the cells, a proportion of the bound nucleic acids are able to dissociate and 
escape from early endosomes into the cytoplasm either to perform a therapeutic function there 
or traffic into the nucleus. 
There are several problems with the chemical delivery strategies: 
• Lipoplexes or polyplexes frequently show instability towards aggregation even before 
entering a cell, especially under conditions of physiological salt levels. They are also 
unstable in the presence of body fluid components such as serum proteins. 
• Neither lipoplexes nor polyplexes are cell type selective. 
• None of them can enter cells very rapidly. 
• Inside the cell, the vast majority of lipoplex and polyplex particles aggregate within late-
endosome compartments producing macroparticles from which nucleic acid can hardly 
dissociate and escape. Moreover, if nucleic acids manage to escape the endosome 
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compartments after delivery, access to the nucleus represents another barrier to nucleic 
acid function. 
2.2.2. Physical delivery systems 
The most important physical delivery options are electroporation, microinjection, 
biolistics or "gene gun" and magnetofection. 
Electroporation is a routine laboratory method for transfection of cultured mammalian 
and bacterial cells. Electrodes inserted into tissue emit controlled electrical pulses that are able 
to create transmembrane potentials sufficient to allow locally administered naked DNA to 
enter cells, probably through the transient pores [38-40]. 
Microinjection involves the direct injection of the therapeutic gene into the desired 
tissue in vivo. Remaining problems with this strategy are to solve the long term expression of 
the introduced gene and to reach sufficient number of the cells of the chosen tissue. 
In the case of biolistic or "gene gun" gold or tungsten particles are coated with DNA and 
accelerated to high speeds by electronic or helium pressure discharge, enabling the coated 
particles to penetrate the target tissues [41-45]. This method causes serious cellular damage. 
In magnetofection magnetic iron-oxide nanoparticles are coated with cationic or anionic 
polymers and naked DNA or recombinant adenoviral vector. Complexes of vectors and 
magnetic particles can transfect cell lines in culture. Under the influence of the magnetic 
fields, transfection/transduction is enhanced up to several orders of magnitude and can be 
directed to a specific area within the cell population in the culture dish [46]. 
2.2.3. Receptor-mediated gene transfer 
In this strategy, the ligand specific to a receptor of a target cell is covalently bound to a 
polycationic molecule such as poly-L-lysine. The polycationic component of this complex is 
capable of making linkage with DNA molecule via electrostatic interactions. After a specific 
binding between the receptor and its ligand this complex can get into the cell by natural 
endocytosis. 
Problematic features of this strategy: 
• The endocytotic vesicles are transported into the lysosomes where they regularly degrade. 
Efficiency of the receptor-mediated gene delivery system can be increased exploiting 
advantage of a parallel adenoviral infection as the adenoviruses are able to crack the 
endosomes subsequently that they managed to get into the cell. 
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• Introduced genes are expressed transiently, though in some cases integration of the foreign 
DNA into the host genome was observed, which can result in significantly prolonged 
expression [47]. 
• Theoretically, any size of foreign DNA can be used, however, a too long DNA molecule 
can break. 
• Though this method enables targeting of particular cells and cell types, the safe and 
efficient targeting is still unsolved. 
2.3. The "ideal" vector 
A key issue in the successful development of gene therapy is the development of 
appropriate vector and delivery systems that allow efficient gene transfer and safe, controlled 
gene expression. Considering the benefits and drawbacks to the current vector systems the 
requirements of a "safe" or "low-risk" vector useable for gene therapy purposes can be 
established [48]. 
• It should be free of elements that enable rearrangements in the host genome 
(recombination, mutation) and the vector must not have negative influence to the function 
of the cell, tissue or organism containing it. 
• It should be stable in the host nucleus without integration into the host genome or designed 
for site-specific integration so that not interfere with the host genomic functions. 
• The copy number of therapeutic gene(s) carried by the vector should be controlled and 
stable. The vector should provide independent and controlled function of the therapeutic 
gene(s). 
• It should accept large (up to Mb size) inserts and ensure the functional stability of the 
insert. 
None of the available DNA vectors meet all of these requirements, except the natural 
"vector" that is the eukaryotic chromosome. The perfection of eukaryotic chromosomes makes 
them the most sophisticated natural gene transfer and operation system. Successful modelling 
this natural system by construction of artificial chromosomes would provide a new vector 
system for gene therapy. 
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3. Building a MAC 
In recent years, basically three main approaches were developed for construction of 
MACs: 
3.1. Synthetic (in vitro) approach 
This strategy involves combination of isolated and cloned structural and functional 
elements of chromosomes in vitro and introduction of them into cells. The main blocks of the 
chromosomes that are necessary to their stable maintenance and replication can be defined as 
centromere, telomeres, autonomously replicating sequence (ARS) and "filling" DNA 
providing appropriate physical size. In addition, normally a chromosome contains genes, 
which in the case of an artificial chromosome also involves a selectable marker gene [48]. 
This methodology was successfully used for construction of artificial chromosomes in 
lower eukaryotes like yeasts Saccharomyces cerevisiae [49] and Schizosaccharomyces pombe 
[50]. In vitro assembly of MACs from cloned elements is hindered by the lack of an isolated, 
functional mammalian centromere, all the other elements of mammalian chromosomes are 
identified, cloned and available. 
3.2. In vivo chromosome fragmentation 
This approach utilizes the telomere-directed fragmentation of existing natural 
chromosomes [51-59]. Different human minichromosomes were generated in this way, they 
show different stability and their purification has not been solved yet. However, such artificial 
human minichromosomes hold the promise of becoming an engineerable vector system [60] 
for human gene therapy. Similarly, naturally occurring centric chromosome fragments [61-64] 
may have the same potential. 
3.3. In vivo "inductive" approach 
This method is based on an inducible intrinsic mechanism, which can facilitate large-
scale amplifications and formation of de novo centromeres and chromosomes [65,66] in 
mammalian cells, upon the integration of exogenous DNA sequences into the specific region 
of the chromosomes. Induced amplification of the pericentric/centromeric region of 
mammalian chromosomes leads to the formation of new chromosomes (Satellite DNA-based 
Artificial Chromosomes = SATACs) that are composed of coamplified satellite DNA and 
exogenous DNA sequences. SATACs can be regarded as artificially generated accessory 
chromosomes composed of predictable DNA sequences, and contain defined genetic 
information. 
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4. The SAT AC technology 
4.1. Generation of satellite DNA-based artificial chromosomes (SATACs) 
In our laboratory, results of transformation experiments revealed that in certain cases, 
integration of exogenous DNA into mouse chromosomes led to the formation of new 
centromeres, dicentric chromosomes, and ultimately, after breakage of dicentric 
chromosomes, de novo chromosomes [65]. Detailed analysis of the chromosomal structures in 
transformed mammalian cells indicated that de novo chromosomes were generated via a large-
scale amplification process [66]. It became clear that large-scale amplification and de novo 
chromosome formation could be induced reproducibly, and independent from the sequence of 
exogenous DNA used in transformation [67]. Analysis of the replication and the amplicon 
structure of de novo formed chromosomes resulted in the identification of a higher order 
replication unit (megareplicon) and a primary replication initiation site (megareplicator) at the 
pericentromeric region of mouse chromosomes. These results suggested that large-scale 
amplification of the centromeric regions as well as the formation of new centromeres, 
chromosome segments, and stable chromosomes could be attributed to a replication-directed 
mechanism [68]. There are several lines of direct and indirect evidences suggesting that the 
ribosomal-DNA (rDNA) containing chromosomal sites can be responsible for the large-scale 
amplification events and the rDNA itself may have importance in the de novo chromosome 
formations [Fodor, K. et al. unpublished]. When the exogenous DNA integrates (Fig. 1A,B) 
into close proximity of a megareplicator, it could lead to a replication error, which initiates 
large-scale amplification (Fig. 1C) of surrounding sequences and brings about the formation 
of large inverted repeats (amplicons). These amplicons are composed of coamplified 
endogenous and exogenous DNA sequences, and they are the building blocks of the new 
chromosomal segments. Amplified centromeric regions can eventually form active centromere 
that leads to the formation of a dicentric chromosome (Fig. ID). The presence of two active 
centromeres on the same chromosome causes specific breakage between the two centromeres 
(Fig. IE), which ultimately brings about the existence of a new chromosome (Fig. IF). During 
the recent years, a number of mouse SATACs have been generated by this technology [65-67, 
Praznovszky, T. et al. unpublished]. 
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Figure 1. Generation of MAC via in vivo inductive approach. A. Mammalian NOR chromosome. B. 
Integration of exogenous DNA into close proximity to a megareplicator leads to a replication error, which 
initiates large-scale amplification (C) of surrounding sequences and brings about the formation of large inverted 
repeats (amplicons). C. These amplicons are composed of coamplified endogenous and exogenous DNA 
sequences, and they are the building blocks of the new chromosomal segments. D. Amplified centromeric 
regions can eventually form active centromere that leads to the formation of a dicentric chromosome. E. The 
presence of two active centromeres on the same chromosome causes specific breakage between the two 
centromeres, which ultimately brings about the existence of a new chromosome (F.). 
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4.2. Generation of human satellite DNA-based artificial chromosomes (hSATACs) 
The question was raised, weather this in vivo inductive approach for generation of 
mammalian artificial chromosomes observed in rodent cells can be applied to other 
mammalian species or it is restricted to rodent cells. To answer this question we attempted to 
generate a human satellite DNA-based artificial chromosome on human chromosome #15. 
This human acrocentric chromosome was chosen, because the NOR (NOR = Nucleolus 
Organizing Region) is fairly well characterized on the short arm of this chromosome. Clinical 
cytogenetics data indicate that polymorphism (spontaneous amplification) of the short arm of 
the human acrocentric chromosomes are the most frequent structural changes without 
phenotypic effect. In higher eukaryotes, ribosomal RNA genes are amplified and organized in 
the form of tandem repeats, their copy number shows significant variance in individuals. 
Based on these facts, it seems unlikely that induced amplification of rDNA or the surrounding 
satellite DNA sequences identified at these chromosomal regions would cause undesirable 
phenotypic effects. To our knowledge, no unsuspected or unwanted coding sequences are 
localized in these chromosomal regions, the only genes found in these chromosomal sites are 
the rRNA genes. Sequences of these regions are suitable basic material to build artificial 
chromosomes. Therefore, the short arm of human acrocentric chromosomes bearing amplified 
ribosomal RNA genes (rRNA, rDNA) and different non-coding satellite DNA sequences, 
seems to be an optimal chromosomal region for inducing de novo chromosome formation. 
We hypothesized, that the basic steps of de novo chromosome formation (Fig. 1) are 
similar in mouse and in human cells. Induction of large-scale amplification in the short arm 
region of human chromosome #15 theoretically would lead to the formation of a de novo 
chromosome that is composed of amplified endogenous sequences of the centromeric/short 
arm region of the human chromosome, and the multiple copies of coamplified exogenous 
DNA sequences. Human SATACs generated on this way would possess all the elements 
necessary to be a stable chromosome: centromere, telomeres, and different noncoding satellite 
DNA sequences that are safe "filling" sequences. Because of the high satellite DNA content 
and the presence of amplified non-satellite sequences, these SATACs would be 
heterochromatic. 
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MATERIALS AND METHODS 
Culture of cell lines and transfection of mammalian cells 
Cell line 94-3 (NIGMS, GM 10664) was produced by fusion of lymphoblasts of a patient with 
a t(X;15) (q25 or q25;q26) and HPRT deficient Chinese-hamster RJK88 cells [69], and was 
obtained from NIGMS Human Genetic Mutant Cell Repository, Coriell Cell Repositories, 
Coriell Institute for Medical Research, Camden, New Jersey, USA. Cells were cultured in 
Dulbecco's Modified Eagle Medium (high glucose) (GibcoBRL) supplemented with 10% heat 
inactivated foetal bovine serum (GibcoBRL) (DMEM-10FBS). The EJ30 human bladder 
carcinoma cell line was maintained in Nutrient Mixture F-12 HAM medium (Sigma) 
containing 10% heat inactivated foetal bovine serum (F12-10FBS). The mouse Satellite DNA-
based Artificial Chromosome (mSATAC) carrying cell lines (produced in our laboratory), the 
mM2ClpCEP8 was cultured in F12-10FBS supplemented with 168pg/ml HygromycinB 
(Merck) and 10pg/ml Puromycin (Sigma), the E420-19 was maintained in Iscove's Modified 
Dulbecco's Medium (GibcoBRL) containing 15% heat inactivated foetal bovine serum 
(IMEM-15FBS) supplemented with 200pg/ml HygromycinB. 
Cotransfection of plasmid DNAs was carried out by calcium-phosphate DNA coprecipitation 
method [70] using 2pg of pCHllO linearized with BamHI, 7pg of pBabePuro opened with 
EcoRI, and lOOpg of carrier rDNA (pK161) linearized with Clal restriction endonuclease per 
semiconfluent 100mm petri dish (5xl06 cells) of 94-3 cell line. Selection of transformants was 
started 48 hours after transfection on 10pg/ml Puromycin in F12-10FBS medium. Stable 
subclones of transformants were maintained in IMEM-10FBS containing 10pg/ml Puromycin. 
DNA and RNA manipulations, plasmid constructs 
All general DNA and RNA manipulations were performed by standard procedures [71]; 
pBabePuro plasmid [72] carrying a mammalian selectable marker gene - the Puromycin 
acetyl-transferase gene -was a kind gift from Dr L. Székely (MTC, Karolinska Institutet, 
Stockholm); pCHllO carrying p-galactosidase gene was obtained from Pharmacia; pK161 
carrying a 9kb coding sequence of mouse ribosomal-DNA in pWE15 (Stratagene) was cloned 
in our laboratory [Fodor, K. et al. unpublished]. ACR-1, a plasmid clone (ATCC 61650) of a 
4.3kb unique sequence distal to the rDNA cluster on the short arm of all 5 human acrocentric 
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(NOR) chromosomes [73] was obtained from the American Type Culture Collection (ATCC), 
Rockville, USA. 
Immunoblotting (Western-blot) 
Western-blotting was performed using standard procedures [71]. The P-galactosidase enzyme 
was detected using 2000x diluted monoclonal anti- p-galactosidase antibody (mouse, 
Promega) and lOOOx dilution of HRPO-conjugated anti-mouse antibody (rabbit, DAKO). 
Chromosome banding 
Constitutive heterochromatin was detected by Giemsa/Barium-hydroxide C-banding staining 
[74] with the modification that after the 1 hour depurination treatment in 0.2N HC1 the slides 
were incubated in prewarmed saturated Barium-hydroxide octahydrate diluted 1:1 with 
distilled water at 50°C for 3-5 minutes. 
PCR amplification of DNA probes 
To avoid cross hybridization of vector sequences, DNA probes were generated by Polymerase 
Chain Reaction. Primers were synthesized on a Pharmacia Gene Assembler. List of forward 
(F) and reverse (R) primers: 
p-galactosidase gene (pCHllO; Pharmacia): LacZ-F (P-galactosidase 121-143) 5'-GAAGAG 
GCCCGCACCGATCGCCC; LacZ-R (p-galactosidase 772-750) 5 '-TTACCCGTAGGTAGT 
CACGCAAC. 
Puromycin acetyl-transferase gene (pBabePuro): Puro-F: 5'-ATGACCGAGTACAAGCCCA 
CGGTGCGC; Puro-R: 5 '-TCAGGCACCGGGCTTGCGGGTCATGCA. 
Human rDNA 5'-external transcribed spacer [75]: HETS-F (1-24 of U13369) 5'-GCTGACA 
CGCTGTCCTCTGGCGAC; HETS-R (U13369: 1520-1497) 5'-GTCCTCTGCGAGCGGGT 
CGCTACG. 
rDNA [76] coding sequence pK161-M7 carrying part of conserved 18S RNA sequence: 
pK161-M7-F: 5'-AGGTGCGTCTGCGGGTTGGGGCTCGTC; pK161-M7-R: 5'-AAGGAT 
CCTCGTT A A AGGATTTA AAGTGG AC. 
Chromosome-specific a-satellites: a-satellite primer 1 (pS12, [Cserpân, I. et al. unpublished], 
X60716: 3920-3898): 5'-CCTGAAAGCGCTCCAAATGTCCA; a-satellite primer 2 (pS12, 
X60716: 3582-3605): 5'-CCTAAGGTGAAAAAGGAAATATCT. 
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Centromeric NotI repeat DNA [77]: Notrep F primer (U53226: 50-75): 5' -GGGTTTA A ATA 
GCCTCGGGCGCAGC; Notrep R primer (U53226: 571-545): 5'-TAGTAGATTGGATTAT 
CTGGAGCCACA. 
P-satellite (distal) hybridizing to the pi3 region of acrocentric chromosomes [78]: p-satdist F 
primer (M81228: 1-26): 5'-ATAAGCTTAGGCAAGAGTTGCATCACCT; P-satdist R primer 
(M81228: 955-930): 5'- TGAAGCTTTGCCTACAGGGGATTGTGAC. 
p-satellite (proximal) hybridizing to the p l l and pi3 regions of acrocentric chromosomes 
[78]: p-satprox F primer (M81226: 38-65): 5'- CAAAGCTTAGACAAGAGTTACATCACC 
T; p-satprox R primer (M81227: 200-176): 5'-TGAAGCTTTCCTAGAGGCACATTGGGA 
C. 
Satellite III DNA [79]: Satellite III F primer (M21305: 1-25): 5'-TGGGAATTCAATAGAAT 
GGAATGGTAT; Satellite III R primer (M21305: 1608-1582): 5'-TGCAATAGAATGGAAT 
GGAATCAACT C. 
147 bp repeat sequence located at the proximal junction of the human rDNA cluster on all 
acrocentric chromosomes [80]: 147rep22 F primer (D31961: 156-177): 5'-CGGGTTGGGAC 
CAGTTAGGT; 147rep22 R primer (D31961: 358-379): 5'-TGGAGTCTGTGAGTCTGTAG 
GT. 
All PCR products listed above were isolated by agarose gel electrophoresis, and identity of the 
fragments was verified by sequencing from the both ends with the amplification primers on an 
ABI Prism automated DNA sequencer. 
The PCR generated telomeric probe was produced by the template-free method [81], and 
labelled either directly by PCR or nick translation (DIG-Nick Translation Kit, Boehringer) 
with DIG-11-dUTP (Boehringer) then purified on Nick Spin Column (Pharmacia). 
DOP-PCR (Degenerate Oligonucleotide-Primed PCR) of flow sorted human Satellite DNA-
based Artificial Chromosomes (hSATAC) was carried out as described [82], with the 
modification that TaKaRa PCR Buffer, dNTP-mix and Taq Polymerase (5U/ 50pl reaction 
volume) were used in the presence of 8pM 6MW single degenerate primer. PCR was 
performed on MiniCycler (JM Research) thermal cycler. Probes generated by DOP-PCR were 
labelled by nick-translation for reverse painting [83]. 
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Immunostaining of chromosomes and in situ hybridization 
Indirect immunofluorescence staining of chromosomes with human LU851 anti-centromere 
serum was performed as described previously [67,84]. Immunostaining with fluorescein 
conjugated anti BrdU monoclonal antibody (Boehringer) was performed according to the 
manufacturer's suggestions. 
For in situ hybridizations biotin (BIO) or digoxigenin (DIG) labelled human genomic painting 
probe (total genomic DNA from EJ30 cell line), a lkb synthetic telomere [Cserpan, I. et al. 
submitted], PCR generated telomere probe [81], 147bp human rDNA flanking sequence 
probe, human 9kb repeat, ACR-1, LacZ PCR, Puro PCR, P-satellite, and satellite III probes 
were prepared by using a nick translation kit (Gibco BRL) according to the manufacturer's 
suggestions. BIO and DIG labelled human 15, 22, and X chromosome specific painting 
probes, D15Z, D22Z1 and DXZ1 a-satellite centromeric probes were obtained and used 
according to the suggestions of the supplier (Oncor). Standard in situ hybridizations were 
performed as described earlier [65]. To detect human chr #15 centromere a BIO or DIG 
labelled monomeric a-satellite variant was also used that was isolated in our laboratory 
[Cserpan, I. et al. unpublished]. The specificity of all human probes used was verified by in 
situ hybridization on human lymphocyte preparations made from the peripheral blood of a 
healthy individual. Microscopy was made with an Olympus AH-2 photomicroscope equipped 
with Quips XL Genetics Workstation system including a Photometries KAF 1400-G2 CCD 
camera (Vysis). 
Flow cytometry 
Metaphase chromosomes were isolated from colchicine-blocked cells and stained with 
Hoechst 33258 and Chromomycin A3 using standard procedures [85]. 
Flow analysis and purification of the hSATACs were performed on a FACS Vantage (BDIS, 
San Jose, CA) equipped with a turbosort option and two Inova 305 lasers (Coherent, Palo 
Alto, CA). Condensing agents were added to the sheath buffer to maintain condensed 
chromosomes after sorting. The final buffer contains 15 mM Tris HC1, 0.1 mM EDTA, 20 
mM NaCl, 1% hexylene glycol, 100 mM glycine, 20 pM spermine and 50 pM spermidine, 
pH:7.6. The sorted SATACs were collected in 1.5 ml screw-capped Eppendorf tubes at 4°C, 
at a sort concentration of approximately lxlO6 chromosomes / ml, which were then stored at 
4°C until needed. For FISH analysis of sorted fractions, aliquots of approximately 10,000 
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chromosomes from each sorted region were placed on glass slides after addition of 0.2% 
formaldehyde for 5 minutes. Slides were then left to dry and dehydrated before being 
hybridized to labelled probes (pBabe Puro plasmid and PCR-generated telomere) using 
standard conditions. Following FISH detection, at least 20 chromosomes were scored for each 
sorted region. 
RESULTS 
Generation of de novo chromosomes 
A Chinese-hamster cell line (94-3) [69] was chosen as the host cell, because it carries 
human acrocentric chromosomes including the chromosome #15. It offers efficient targeting 
of the human ribosomal region and since hamster chromosomes carry practically no large 
constitutive heterochromatic segments, amplified human heterochromatic regions can be 
detected easily by Giemsa staining technique (C-banding) on Chinese-hamster background. 
Initial characterization of the 94-3 cell line revealed that in 100% of the cells, human 
t(X;15) chromosome (referred herein as t(X;15q25)) and human chromosome #22 were 
retained. In addition, 15% of the cells had human/hamster translocated chromosomes, and 
20% of the cells carried human chromosome fragments (NIGMS Human Genetic Mutant Cell 
Repository). 
A I It I C 
Figure 2. Human chromosomes in the host 94-3 cell line. Two color FISH on metaphases of 94-3 cells with 
biotin-labelled human genomic painting probe (green signal), and digoxigenin (DIG)-labelled D15Z probe (pink-
white signals). A. human chromosomes t(X;15q25) and #22. B. Human chr t(X;15q25) and a small human 
chromosome fragment with chr #15 centromere. C. Acrocentric hamster chromosome with translocated human 
chr #15 centromere and short arm region. 
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First we verified the presence of human chromosomes in 94-3 cells by in situ 
hybridizations with biotin labelled human genomic DNA probe, and also with biotin labelled 
human a-satellite DNA sequences, and confirmed that 96.8% of the cells carried human 
chromosomal material. Two hundred and ninety-six metaphases of 94-3 cells were analyzed 
in detail by in situ hybridization using a human genomic painting probe (EJ30), human 
chromosome-specific painting probes (chr #15, #22, and X), and human chromosome-specific 
a-satellite centromeric probes (D15Z, D22Z1, and DXZ1). Details of the FISH analysis of the 
94-3 cell line is presented in Figure 2 and Table 1. 
Table 1. Analysis of 94-3 cell line by FISH 
Human chromosome 
(intact or fragment) FISH probes 
Percentage in 296 
metaphases analyzed 
Human chromosome material Genomic painting 96.8 
Chromosome t(X;15q25) 15 painting, D15Z 56.0 
Chromosome X X painting 56.0 
Chromosome # 22 22 painting, D22Z1 15.5 
Chr #15 centric fragment D15Z 3.4 
Chr # 22 centric fragment D22Z1 34.1 
Chr X centromere DXZ1 0.0 
Translocated 
human/hamster chromosome* 
Genomic painting, 
D15Z, and D22Z1 24.7 
* These metaphases contained an acrocentric hamster chromosome with a centromere and short arm 
composed of human chromosomal material. The majority (89%) of these translocated chromosomes 
showed centromeric hybridization with D22Z1, 7% of the centromeres were labelled with D15Z (Fig. 
2C), and in 4% of the centromeres no human alphoid sequences were detected. 
Our aim was to integrate marker gene(s) into the ribosomal DNA region (rDNA, 
NOR=Nucleolus Organising Region) of a human chromosome via site-specific integration, 
and induce large-scale amplification and de novo chromosome formation. Large amounts of 
target sequences used as a carrier in cotransfection, can promote site-specific integration of 
the exogenous DNA sequences [67,86]. The ribosomal RNA coding sequences are highly 
conserved in eukaryotes (from yeast to human), therefore mouse rDNA sequences are suitable 
for targeting the rDNA region of human (or hamster) chromosomes. In the case of human 
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acrocentric chromosomes, besides the rDNA, a number of neighbouring endogenous 
sequences have been identified in the NOR regions (Fig. 3). These sequences are: the 
proximal 147bp repeat [80] proximal and distal [3-satellite [87], ACR-1, a unique flanking 
sequence distal to the rDNA cluster [73], a methylated human 9-kb repetitive sequence [77] 
(Not / repeat), telomeric sequences on the distal ends, D15Z1 satellite III |79], and D15Z a -
satellite DNA sequences towards the centromere. Except for ACR-1 sequences, all these 
sequence elements were detectable on the human chr t(X;15q25) in the 94-3 cell line by in 
situ hybridization with the corresponding probes. 
Figure 3. DNA composition of the short arm of the human chromosome #15. In the case of human 
acrocentric chromosomes, besides the rDNA, a number of neighbouring endogenous sequences have been 
identified in the NOR. These sequences from the centromere towards the telomere are: D15Z a-satellite DNA 
sequences, D15Z1 satellite III, proximal P-satellite, 147bp repeat, rDNA cluster, distal P-satellite, ACR-1 
specific to the short arm of human acrocantric chromosomes, a methylated human 9-kb repetitive sequence (Not 
/repeat), and telomeric sequences on the distal ends. 
To test whether large-scale amplification can be induced on human chromosomes in a 
host cell of another species, a semiconfluent culture of 94-3 cells was cotransfected with a 
mixture of plasmid DNAs of pBabePuro linearized with EcoRI, pCHllO linearized with 
BamHI, and carrier rDNA (pK161) linearized with Clal restriction endonucleases as 
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described in the methods section. After 10-16 days of puromycin selection, 68 individual 
puromycin resistant colonies were rescued, and propagated for an additional 18-25 days. 
Initial cytological analyses of the clones were performed on day 28-42 after transfection, and 
at the same time the primary screening for amplification was carried out by Southern blot 
hybridization with a plasmid probe on EcoRI digested DNAs purified from the individual 
clones. 
The generation time of the primary clones was estimated by BrdU incorporation [68], 
and was found to be 14-16 hours. Therefore, these primary clones represented cultures of 
45th-70th generations after transfection. 
Analysis of primary clones 
Over 50% of the 68 rescued clones showed "high copy number" hybridization signals 
with plasmid probe indicating either the integration of multiple copies of the bacterial 
constructs or the amplification of the integrated exogenous DNA sequences. Representative 
examples of the hybridizations on the primary clones are shown in Figure 4. Twenty-one 
primary clones showed (3-galactosidase expression detected with the standard LacZ staining 
technique. 
t « • 
* 
Figure 4. Southern blot 
hybridization on the primary 
clones. Representative example of 
Southern blot hybridization on 
~10 pg Eco RI digested DNA of 
34 primary clones with 
pBabePuro plasmid probe. Lanes 
representing clones C23 and C48 
are marked with asterisks. 
•ts a 
* 
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The first cytological analysis was made by C-banding [74], Two clones (C23 and C48) 
were found to carry large de novo formed heterochromatic segments. In clone C23, 71% of 
the cells contained a typical "sausage" chromosome with a heterochromatic arm of 30-150MB 
(Fig. 5A). The sizes of the de novo structures were estimated by comparing them to the 250-
300Mb sized hamster chromosome #1. Fifteen per cent of the C48 metaphases also contained 
heterochromatic "sausage" chromosomes (Fig. 5D). In addition to the amplified sausage 
chromosomes, free de novo heterochromatic chromosomes were observed in 5 out of 347 
metaphases of the C23 clone (Fig. 5B), and heterochromatic chromosomes of different size 
(-50-250MB) were found in 107 out of 219 metaphases of the C48 clone (Fig. 5C). The 
heterochromatic segments in both clones were derived from the short arm of an acrocentric 
chromosome. Fluorescent in situ hybridization revealed one integration site of pBabePuro 
sequence in the short arm of an acrocentric chromosome in clone C23, and there were two 
integration sites in clone C48: one in the centromeric region of an acrocentric chromosome, 
and the other in a tiny metacentric chromosome. Initiation of the amplification detected by in 
situ hybridization with the D15Z probe correlated with these integration sites, and enlarged 
human chr #15 a-satellite (D15Z) regions were detected on the acrocentrics, and on a centric 
fragment of human chr #15 (not shown). 
Figure 5. Heterochromati 
staining on C23 and C4: 
primary clones. A. "Sausage 
chromosome in C23. E 
Independent heterochromati 
chromosome in C23 (arrow). C 
Independent heterochromati 
chromosome in C48 metaphas 
(arrow). D. Heterochromati 
"sausage" chromosome in C48. 
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Concurrent with the C-banding, results of in situ hybridizations (FISH) with human 
genomic, human chr #15 and chr #22 painting, and centromere specific probes showed that 
the large amplified regions were of human origin and contained human D15Z sequences. In 
clone C23, the short arm of human chr t(X;15q25) hosted the new amplified arm, while in 
clone C48, the "sausage" chromosome derived from the acrocentric hamster chromosome 
with translocated human chr #15cen/short arm region (not shown). In situ hybridization on 
C23 and C48 metaphases with chr #15cen/PuroPCR probes and immunostaining with LU851 
human anti -centromere serum [65] confirmed that these de novo formed heterochromatic 
chromosomes carried amplified exogenous DNA (Fig. 6D,F,H) and functional centromeres 
(Fig. 6C,E,G). Standard immunostaining on hSATACs with anti-centromere serum resulted 
in a typical centromeric label showing terminally located kinetochores. In addition, faint 
signals along the amplified chromosomal segments were observed (Fig. 6C,E,G). 
The morphology of the transitional structures found in the primary clones confirmed 
that the basic steps of de novo chromosome formations are similar to that of were observed on 
mouse chromosomes: i/ the integration(s) of exogenous DNA into centromeric regions (Fig. 
6B) that induces large-scale amplifications; ii/ the formation of heterochromatic arms with an 
active centromere ("sausage" chromosome formation) (Fig. 6C,D), iii/ breakage of the 
dicentric "sausage" chromosome separated the heterochromatic arm (Fig. 6E,F), which 
finally became an independent new chromosome (Fig. 6G,H). 
Isolation of stable subclones 
The occurrence of hSATACs in primary clones indicated that they were mitotically 
stable, and might allow selection of stable subclones. By single-cell subcloning we managed 
to establish subclones carrying stable hSATACs of different size and morphology from both 
primary clones (Fig. 7). We regarded subclones as stable when at least 98 % of cells retained 
the hSATAC under selective conditions, and more than 95% of cells retained cytologically 
unchanged SATAC under non-selective conditions cultured for 33 days (~50 generations). In 
the two most extensively used subclones (C23-Z41/15 and C48-5B4-D2), under normal 
selective growth hSATACs remained cytologically unchanged after 274 and 731 generations, 
respectively. 
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Figure 6. Generation 
of human satellite 
DNA-based artificial 
chromosomes in vivo. 
Subsequent steps of 
induced de novo 
chromosome formations 
are shown on B-H. 
Chromosomes on A,D,F,H 
were counterstained with 
DAPI (blue), overlapping 
green and red signals of the 
probes appear as pink-
white. Chromosomes on B. 
C,E,G were counterstained 
with propidium iodide 
(red). A. In situ 
hybridization on human 
chromosome #15 (arrow) 
in a human/hamster 
monochromosomal hybrid 
cell with human 
chromosome specific 
painting probe (green) and 
human chromosome #15 
centromere-specific alpha satellite DNA (red) probes. B. Yellow in situ hybridization signal with plasmid probe 
(arrow) demonstrates the integration of exogenous DNA into the centromeric/short arm region of chromosome 
#15 in a primary transformant cell. C. Large-scale amplification of the centromeric/short arm region of 
chromosome #15 result in the formation of a new chromosome arm with a de novo centromere. Arrow points to 
the newly formed centromere of the dicentric "sausage" chromosome. Yellow signals correspond to the 
centromeres visualized by indirect immunofluorescence with LU851 human anti-centromere antibody D. Two 
color in situ hybridization on the "sausage" chromosome with chromosome #15 a-satellite (D15Z1) (red) and 
exogenous DNA (green) probes. E-F. Breakage of the dicentric chromosome (arrows). The arrowhead on F 
indicates the formerly dicentric chromosome. G-H. Independent de novo SATACs (arrows) with anti centromere 
staining (G), and with in situ hybridization. Probes are the same as on C, E and D, F. (Note the faint double 
signals on the amplified chromosome arms (C, E) and on the SATAC (G) that may correspond to multiple 
inactive centromeres.) 
SINGLE-CELL SUBCLONING, 
CLONES with INDEPENDENT. STABLE, 
HUMAN SATELLITE DNA-BASED 
ARTIFICIAL CHROMOSOME (hSATAC) 
MULTIPLE COPIES of 
SATELLITE,"FOREIGN',and DL SEQUENCES 
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Figure 7. Chromosomes of stable hSATAC subclones with C-banding and FISH. A. Heterochromatic 
staining of clone C23-Z41/15. B. Two-color FISH with DIG-labelled human chr #15 a-satellite D15Z (red) and 
biotin labelled (green) human satellite III probes. Intense colocalized signals appear pink/white. C. Clone C48-
6B5-D1 by C-banding D. FISH with DIG labelled (red) D15Z a-satellite probe. E. FISH on clone C48-6D6 with 
human D15Z a-satellite (red) probe. F. C-band staining on clone C48-6D6. G. FISH on clone C48-5B4-D2 with 
D15Z a-satellite (red), biotin labelled pBabePuro plasmid (pink/white) probes, and with biotin labelled p-
satellite probe (green) that localized exclusively on the tip of one hSATAC. H. C-banding of clone C48-5B4-D2. 
Arrowheads on pictures point to the hSATACs. Chromosomes on B,D,E,G were counterstained with DAPI 
(blue). 
Sequence composition of hSATACs 
To identify DNA sequences present on the hSATACs other than the alpha-satellite 
(D15Z) and exogeneous sequences, in situ hybridizations were also performed with a number 
of different probes of known human DNA sequences specific to the short arm regions of 
acrocentric chromosomes (Table 2). Analysis of sequence composition of hSATAC of clone 
C23-Z41/15 by FISH is demonstrated on Figure 8. All known sequences specific to the short 
arm of human chr #15 (Fig. 3) from the centromere (a-satellite and satellite III see Fig. 7B, 
Fig. 8E) to the telomere (ACR-1 and telomeric repeats see Fig. 8K,L) were detected on the 
hSATAC. Results of in situ hybridizations revealed that the most abundant sequences on the 
/ \ 
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Figure 8. Sequence 
analysis of hSATAC of 
clone C23-Z41/15 by 
FISH. Chromosomes are 
counterstained with DAPI 
(blue), hSATAC is indicated 
with arrowheads. A. Indirect 
immunofluorescence staining 
of hSATAC with LU-851 anti-
centromere serum showing 
terminally located centromere. 
B. FISH on the same 
metaphase with human chr #15 
monomelic a-satellite probe 
(red) localized exclusively in 
the centromere and with 
plasmide probe (pBabePuro) 
(green) showing interspersed 
signal on the hSATAC. C. 
Interspersed LacZ (green) 
signal on the hSATAC. D. 
Colocalized (pink-white) Puro 
PCR (green) and D15Z (red) 
signals. E. Centromeric and 
interspersed localization of 
satellite III (D15Z1) sequences (green).F. Colocalized M7 rDNA (green) and D15Z (red) signals. G. Human 
rDNA externally transcribed spacer (HETS) (green) and D15Z (red) signals. H. Interspersed signal (green) with 
Not I centromeric repeat probe. I. Colocalized DIG labelled P-satellite (red) and biotin labelled D15Z (green) 
signals. J. Biotin (green) 147bp repeat probe. K. Two color FISH with D15Z (red) and ACR-1 (green) probes. L. 
Two color FISH with biotin labelled D15Z (green) and DIG labelled PCR generated telomere (red) probes on 
hSATAC, the presence of centromeric telomere sequences are characteristic to some hamster chromosomes. 
hSATACs were: chr #15 a-satellite (D15Z) (Fig. 8D,F,G,I,K,L), human rDNA (Fig. 8F,G), 
satellite III (D15Z1) (Fig. 7B, Fig. 8E), p-satellite (both distal and proximal) (Fig. 7G, Fig. 
81), Not I repeat (Fig. 8H), 147bp repeat (Fig. 8J), and exogenous DNA (Fig. 8B-D). These 
observations suggest that the heterochromatic nature of the newly formed chromosomes can 
be attributed to the presence of these amplified DNA sequences. The presence of interspersed 
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telomeric sequences on hSATACs (Fig. 11B: R1&2) indicates that these sequences also 
coamplified with the other sequences specific to the short arm of human acrocentric 
chromosomes. Following the chromosome breakage that occur during the SATAC formation, 
these interspersed telomeric repeats may contribute to the stability of the de novo 
chromosomes. 
Table 2. Sequence analysis of hSATACs by FISH 
Probes 
hSATAC clones 
C23-Z41/15 C48-6D6 C48-5B4-D2* C48-6B5-D1 
22cen D22Z1 - - - - -
15cenD15Z + + + + + 
Puro PCR + + + + + 
LacZ PCR + - - - -
rDNA (M7) + + + + + 
rDNA HETS + - - + -
Telomere + + + + + 
147bp repeat + + + + + 
9kb Not I repeat + + - + -
ACR + - - - -
P-satellite + - - + -
Satellite-Ill + - - + -
* C48-5B4-D2 cell line contains two hSATACs with similar morphology but different 
sequence composition (for an example see Fig. 7G). 
Human SATACs were separated by FACS (see below) from clones of C23 and of C48 
as well. Separated hSATACs were used as template in DOP-PCR [82], and the product was 
labelled for FISH and were used in reverse painting [83] on hamster and human 
chromosomes. Results of reverse painting experiments revealed that the hSATACs of C23 
clones carry no detectable amount of hamster specific sequences. SATACs of C48 clone, 
which derived from the acrocentric hamster chromosome with translocated human 
chr#15cen/short arm region hamster centromeric sequence was found (Fig. 9). This sequence 
was cloned, sequenced and identified as hamster chr #5 centromeric repeat [Szakái, B. et al. 
unpublished]. 
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Figure 9. Sequence analysis of hSATAC of 
clone C48-5B4-D2 by reverse painting on 
Chinese-hamster spleen lymphocytes. Two 
color FISH with biotin labelled hSATAC 
specific painting probe generated by DOP-
PCR from purified hSATACs (green) 
(asterisks), and DIG labelled PCR generated 
telomere (red) probes on Chinese hamster 
chromosomes. Chromosomes are 
counterstained with DAPI (blue). 
Expression of the marker genes from heterochromatic hSATACs 
Twenty-one out of 68 primary clones showed (3-galactosidase expression by 
conventional lacZ staining. Clone C23 is one of the 21 P-galactosidase positive primary 
clones. Expression of the non-selected marker gene in hSATAC carrying subclones (C23-
Z41/15) of C23 primary clone was confirmed by conventional LacZ staining (Fig. 10B) and 
by immunoblotting using monoclonal P-galactosidase antibody (Fig. 10A). 
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Figure 10. Expression of the marker genes from heterochromatic hSATACs. Detection of the expression of 
the non-selected marker gene (P-galactosidase): A. Immunoblotting with anti-P-galactosidase antibody. Protein 
marker (1), hSATAC subclones (2-4), proteins of a mouse SAT AC carrying cell line containing 0.1% p-
galactosidase enzyme (5), host cell line 94-3 (6). B. LacZ staining on hSATAC carrying cells (C23-Z41/15). 
Detection of the expression of the selected marker gene (puromycin acetyl-transferase): C. Northern blot 
hybridization with puromycin PCR probe. Mouse SATAC carrying cell line expressing puromycin acetyl-
transferase (1), host cell line 94-3 (2), hSATAC subclones (3-7). 
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Expression of selectable marker gene (puromycin acetyl-transferase) was detected by 
resistance to lOpg/ml puromycin that is two fold of lethal concentration established for the 
host cell line (94-3). Z41/15 cells were also tested at high concentration of antibiotics, and up 
to 150pg/ml puromycin no killing effect or stunted growth were observed. Some subclones of 
C23 cells can tolerate 300pg/ml Puromycin concentration as well. In addition, Northern 
hybridizations were also used to detect the mRNA of the selectable marker gene in subclones 
of both C48 and C23 primary clones (Fig. IOC). 
Separation of hSATACs 
Based on the difference between the human SATAC and the "natural" hamster 
chromosomes with respect to their DNA content, hSATACs can be purified efficiently by 
flow cytometry. The cell line containing two hSATACs, C48-5B4-D2, was used to 
demonstrate the separation of hSATACs by flow cytometry. Metaphase chromosomes were 
isolated from mitotic cells, stained with two fluorescent dyes, and passed through two laser 
beams: by plotting the fluorescence of each dye and chromosome, a "flow karyotype" was 
obtained from both the parental cell line (94-3) (Fig. 11 A) and the hSATAC cell line (Fig. 
11B). The two novel clusters (R1 and R2) in the hSATAC line were assumed to represent the 
two hSATACs. Chromosomes from these two clusters were physically purified by the 
cytometer and placed on slides for FISH analysis. Two other regions (R3 and R4) were also 
isolated as controls. The FISH experiment using either plasmid probes or PCR generated 
telomere probes showed conclusively that the chromosomes isolated in regions 1 and 2 
contained interspersed plasmid/telomere DNA consistent with hSATACs, while the 
chromosomes in regions 3 and 4 contained no plasmid DNA, and the telomere DNA signal 
was consistent with hamster chromosomes (Fig. 11B: R3-4). From R1 and R2, 62 
chromosomes were analysed by in situ hybridization and 60 chromosomes proved to be 
hSATACs. Based on these results, the purity of separated hSATACs was >96%. 
Purified SATACs can be used in quality control by FISH as templates to generate 
hybridization probes with degenerate oligonucleotide primed PCR (DOP-PCR) [82]. 
Fluorescent in situ hybridization with these probes to the chromosomes of host cell and 
SATACs can serve in monitoring the purity of separated SATACs, and to analyze the 
sequence composition of SATACs at the level of FISH detection [83]. 
E. Csonka: Generation of prototype human satellite DNA-based artificial chromosofnes 
34 
Chromomycin A3 Chromomycin A3 
A B 
Figure 11. Separation of hSATACs with fluorescence activated cell sorter (FACS). A. FACS karyotype of 
the host 94-3 cell line. B. FACS karyotype of the C48-5B4-D2 clone containing two hSATACs. R1-R4 represent 
the separated chromosome fractions, on the right side of the panel the verification of the separated chromosomes 
are shown by in situ hybridization with biotin-labelled pBabePuro probe (green) (Rl), and DIG labelled PCR 
generated telomere probe (red) (R1-R4) on DAPI counterstained chromosomes (blue). 
A stable cell line with a functional artificial chromosome has been established via direct 
chromosome uptake of isolated hSATAC by cultured human cells [Csonka, E. et al. 
unpublished] (Fig. 12). This indicates the feasibility of direct transfer of purified hSATACs 
by "wrapping" them with various membrane-active compounds or by other physical and 
chemical methods. 
Figure 12. Chromosomes of a human 
fibrosarcoma cell line established by direct 
uptake of an isolated hSATAC. In situ 
hybridization with hSATAC specific painting probe 
(green) generated with degenerate oligonucleotide 
primed PCR from FACS purified hSATACs. 
Chromosomes are counterstained with propidium 
iodide (red). 
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DISCUSSION 
We described the successful generation of the human counterpart of mouse satellite 
DNA-based artificial chromosomes [67], We demonstrated that human satellite DNA-based 
artificial chromosomes can now be generated via induced large-scale amplification on the 
centromeric/short arm region of the human acrocentric chromosomes. In independent 
experiments, different hSATACs have been generated from the short arm of the human 
chromosome #15, in a human/hamster monochromosomal hybrid cell line (94-3) [88] and in 
HT-1080 human fibrosarcoma cells [Csonka, E. et al. unpublished] (Fig. 13). 
/ 
Figure 13. Human SATACs generated from 
sequences of the centromeric/short-arm region of 
human chromosome #15 in human fibrosarcoma 
cell. Two color in situ hybridization on hSATAC 
(arrow) carrying multiple copies of an ~120kb 
sequence of the short arm region of human 
chromosome #3. Green signals correspond to the 
human chromosome #15 a-satellite DNA, red signals 
label the ~120kb human sequence of chromosome #3. 
For an estimation of the amount of payload DNA 
carried by the SATAC, compare the intensity of the single copy hybridization signals (red) on chromosome 
#3 to the intensity on the SATAC (pink-white). Chromosomes are counterstained with DAPI (blue). 
These results confirm that the methodology we initially used in mouse cells to create 
mouse satellite DNA-based artificial chromosomes is reproducible, and can be successfully 
applied to other species, and also in other host cells using different foreign DNA sequences. 
The ability to target amplifiable sites, as we did here using rDNA sequences, greatly 
accelerates the generation of SATACs. These mammalian artificial chromosomes are formed 
in vivo and acquire all the structural and functional elements necessary for chromosome 
formation from endogenous sequences. Consequently, the successful generation of de novo 
chromosomes, at the same time, is the ultimate test of the functionality of these components 
together with the integrated exogenous genetic material. 
Human-hamster hybrid cells used in these experiments proved to be an efficient 
platform for de novo chromosome formation, and for establishing stable cell lines with 
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hSATACs. The short arms of the human acrocentric chromosomes are specific chromosomal 
regions (NOR) with well characterized DNA sequences. Amplification of these endogenous 
sequences of the short arms offers several advantages, which make these sites ideal for the 
construction of human artificial chromosomes in vivo: i/ Coamplified telomeric sequences can 
provide functioning telomeres for the de novo formed chromosome, ii/ The non-coding 
centromeric satellite DNAs lack transcription units for undesired and unknown genes and 
hence are safe "filling" sequences, iii/ Despite of the heterochromatic nature of the hSATACs, 
coamplified rDNA sequences may provide a suitable chromatin environment [89,90] for the 
expression of the integrated "foreign" gene(s). iv/ Non-coding repeated sequences specific to 
the short arm of the human acrocentric chromosomes can serve as useful markers to 
characterize newly formed chromosomes, v/ With respect to the possible use of hSATACs as 
vectors in human gene therapy, it is important that apart from the rRNA genes, no 
unsuspected or unwanted coding sequences are localized in these chromosomal regions, and it 
would seem unlikely that the amplification of rDNA or the known sequences identified at 
these chromosomal regions would cause phenotypic effects. In contrast, at least in tissue 
culture, amplification of rDNA presented selective advantage [91]. The spontaneous 
amplification of the short arm of the human acrocentric chromosomes is the most frequent 
structural polymorphism without phenotypic effect [92]. Follow-up studies on an unselected 
group of children with small supernumerary chromosomes revealed that in all 12 cases out of 
14, where the inherited or de novo extra chromosomes were derived from the short arm of a 
NOR chromosome, the affected children developed normally [93]. Additionally there is a 
report of 8 healthy members of a three-generation family carrying a small supernumerary 
chromosome derived from the short arm of an acrocentric chromosome [94]. These examples 
indicate the existence of intrinsic cellular mechanisms that give rise to stable de novo 
chromosomes under natural circumstances without any dire consequences. The in vivo 
generation of SATACs is based upon the induction of these intrinsic mechanisms, and it is 
conceivable that satellite DNA-based artificial chromosomes formed by induced large-scale 
amplifications on the short arm of human chromosomes may become a "safe" or "low risk" 
vector in gene therapy. 
The cell population of primary clones represents 45-70 generations of transfected cells, 
and the presence of hSATACs in these Clones indicated that the de novo chromosomes 
appeared early after the transfection. We showed that stable subclones could be established 
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with different hSATACs from the primary clones, and that these de novo chromosomes were 
retained in the majority of the cells. These results indicate that hSATACs are mitotically 
stable, and demonstrate the feasibility and relative ease of establishing stable cell lines with 
hSATACs by prolonged culturing and repeated subclonings. 
We have shown that mouse SATACs can be efficiently transferred by microcell 
mediated chromosome transfer to mammalian cells derived from different species [95] 
preserving their structural integrity, stability, and function. Further engineering of hSATACs 
can be performed with targeted integration of the required exogenous genetic material either 
in the host cells or in a homologous recombination system such as chicken DT-40 cells [96]. 
We demonstrated that hSATACs could be purified efficiently from the host cell chromosomes 
by flow cytometry. Purified hSATACs may allow their extensive molecular characterization 
and may be used for direct chromosome transfer. Recent results of direct transfer experiments 
with mouse SATACs indicated that the FACS procedure did not abolish the biological 
activity of purified artificial chromosomes. Furthermore, by pronuclear microinjection of 
FACS purified artificial chromosomes, successful generation of transgenic mice and germline 
transmission of mouse SAT AC was demonstrated [97]. 
The generation of prototype hSATACs demonstrates that the inductive approach 
represents an effective method for construction of human artificial chromosomes in vivo. In 
one transfection experiment, and by rounds of single-cell subcloning, different stable clones 
could be produced with different hSATACs. We showed that DNA sequences specific to the 
centromeric/short arm regions of human chromosomes are appropriate tags, and useful 
markers in characterizing the hSATACs generated in the NOR region of human 
chromosomes. For possible human gene therapy applications, construction of hSATACs on a 
human NOR chromosome of choice in stable monochromosomal human-rodent hybrids [98], 
may serve as an appropriate platform. 
SATACs have already complied some of the milestones considered necessary on the 
way of becoming a vector. These milestones are: 
1. Generation of artificial chromosomes on a reproducible manner, from predictable DNA 
sequences [88]. 
2. Stable transfer of SATACs into different cells and embryos preserving the structural 
integrity and function [95,97]. 
3. Large-scale purification of SATACs [85]. 
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4. Generation of transgenic animals with purified SATACs and germline transmission of 
these mammalian artificial chromosomes [97]. 
5. Tissue specific expression of therapeutic gene in transgenic animals (unpublished). 
Considering the diversity of the requirements of different gene therapy applications it is 
conceivable that there will be no prevailing or ideal vector. Each application must have its 
optimal or perfect vector that complies best with the requirements of safety and serves the 
therapeutic goal at the possible highest level. For the success of gene therapy, different vector 
systems should be complementary rather then competitors. Artificial chromosomes will be 
suitable vectors in those applications where the stable, persistent or controlled gene expression 
can only be secured by the use of large (>100kb) therapeutic gene(s) or with gene complexes 
with appropriate "built-in" controlling elements. The present limitation, which applies to all 
existing vector systems, is the efficient delivery of the vectors into the target cells or tissues. 
Significant improvement of efficiency and specificity of delivery methods is one of the major 
tasks for the basic science that has to be accomplished in the future. Until then, in somatic 
gene therapy, the use of artificial chromosomes will be limited to ex vivo applications, 
particularly in combination with stem cell technology. 
In general, the most imminent tasks to realize the practical applications of artificial 
chromosomes in ex vivo somatic gene therapy can be summarized below [99]. 
1. Construction of therapeutic artificial chromosomes preferably with appropriate control of 
the expression of therapeutic gene(s). 
2. Improved and efficient delivery of artificial chromosomes, preferably on a cell-specific 
manner. 
3. Demonstration of therapeutic effect(s) in appropriate cellular or/and animal model 
systems. 
4. Accomplishment of pre-clinical animal systems to test the toxicity, immunogeneicity, 
stability, and the long term-effect of artificial chromosomes. 
5. Establishment of artificial chromosome vector-specific criteria for safety and quality 
control. 
The successful generation of transgenic animals by pronuclear injection of purified 
artificial chromosomes made the germline gene therapy technically feasible, and refuelled 
public debate on the engineering of the human germline. Obviously, there are serious ethical 
and social issues related to germline gene therapy that have to be discussed. For the present, 
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engineering the human germline is a distant possibility of the future, and the debate on this is 
directed towards the principle of germline therapy. To put the principle of germline gene 
therapy into practice will require considerable time and substantial basic and clinical research. 
Impartial discussions on the implementation of germline gene therapy will be possible only 
when solid scientific facts will be available on the safety of a proposed protocol, and sufficient 
data will be accumulated from animal models on the potential risks and benefits of germline 
engineering. When the time comes, impartial discussions should also mean to give voice to the 
affected families and individuals facing incurable diseases. 
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SUMMARY 
We demonstrated that: 
- The "in vivo" construction of artificial chromosomes is an efficient and reproducible 
method, and this technology can be successfully applied for generation of human 
artificial chromosomes. 
- Stable heterochromatic human SATACs can be generated in different mammalian 
cell lines from predictable endogenous DNA sequences. 
- Human SATACs can carry >Mb size "payload" DNA. 
- Based on the difference of the DNA content between the human SATACs and the 
natural chromosomes, they can be purified efficiently by flow cytometry. 
- Human SATACs purified with dual laser beam cell sorter are suitable for quality 
control of artificial chromosomes by FISH (DOP-PCR, reverse painting). 
- Purification of human SATACs makes possible their direct transfer into target cells. 
- Human SATACs are heterochromatic, however, they provide suitable chromosomal 
environment for the stable expression of the integrated exogenous genetic material. 
- Human SATACs are composed of genetically "neutral" DNA sequences. 
- Based on the characteristics of prototype human SATACs they can serve as a start-
point in developing a "safe" or "low risk" artificial chromosome-based vector system 
for gene therapy. 
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